Form 4: Semler Scientific CFO Acquires 40,000 Stock Options

Semler Scientific's Chief Financial Officer, Renae Cormier, has acquired 40,000 stock options, exercisable over a four-year vesting period.

Summary

• Renae Cormier, the Chief Financial Officer of Semler Scientific, Inc., has reported the acquisition of 40,000 stock options.
• These options were granted on January 6, 2025, with an exercise price of $58.94 per share.
• The options vest over a four-year period, with 1/4th vesting on the first anniversary of the grant date and the remaining vesting monthly over the following three years.
• The options expire on January 6, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by the CFO could indicate confidence in the company's future performance.
• The vesting schedule aligns the CFO's interests with the long-term success of the company.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation across the technology and healthcare sectors, similar to companies like Medtronic or Boston Scientific.
• The four-year vesting schedule is also a typical practice to ensure long-term commitment from executives.

Stakeholder Impact

• The stock option grant could positively impact shareholder sentiment by demonstrating management's commitment to the company's long-term success.
• The vesting schedule ensures that the CFO's interests are aligned with the long-term performance of the company, which is beneficial for shareholders.

Key Dates

Keywords

stock options, insider trading, Semler Scientific, CFO, Renae Cormier, equity, vesting